Hitgen Incis A Biotechnology Company Based In Chengdufounded In 2012With Additional Subsidiaries In Cambridgeukand Houstonusathe Company Specializes In Innovative Drug Discoveryfocusing On Developing Novel Medicines And Agrochemicalshitgen Collaborates With Numerous Global Biopharmaceutical Organizationsleveraging Advanced Technology Platforms To Enhance Drug Development Processes The Company Utilizes Several Core Technology Platformsincluding Dna Encoded Libraries For High Throughput Screeningfragment Based Drug Discoverystructure Based Drug Designand Oligonucleotide Based Therapeuticshitgen Offers Comprehensive Drug Discovery Solutionsproviding Services From Early Stage Discovery To Clinical Trial Preparationthey Also Engage In Technical Consulting And Licensingsupporting Partners With Customized Research Servicestheir Therapeutic Focus Includes Oncologycardiovascularrespiratoryand Metabolic Diseases Hitgen Has Established Strategic Partnershipsincluding A Collaboration With Bridge Biotherapeutics For Anti Cancer Drug Developmentthe Company Has Received Recognition For Its Innovative Contributionsincluding Thecas Registry Innovatorcertificate From The American Chemical Societydrjin Li Serves As The Ceoleading The Company In Its Mission To Advance Biomedical Innovation
